Cimzia's Phase III Data First In Non-Radiographic Axial Spondyloarthritis
Top-line Phase III data suggests UCB Pharma's Cimzia has benefits in a specific type of axial spondyloarthrits, with the findings expected to be submitted to the US FDA in the coming months.
You may also be interested in...
Taltz has sailed through the latest trial in Lilly’s COAST program, in non-radiographic axial spondyloarthritis, but choppy waters may be ahead; meanwhile, Lilly signs an immunology deal with Avidity Biosciences.
Lilly reported positive results for Taltz in a second Phase III study in ankylosing spondylitis and plans to file for FDA approval this year, which would give the IL-17A inhibitor a label similar to its rival Cosentyx, for which Novartis is working hard to build, maintain and grow market share.
Evotec has gained access to next-generation antisense technology through forging a strategic partnership with the small German biotech, Secarna, and they aim to make available a joint antisense pipeline of new therapeutic options for industry partners.